Cacao flavor enhancement using cyclodextrins and starch derivatives
A novel approach using β-cyclodextrin to improve cacao derivatives by reducing bitterness and off flavors while preserving desirable attributes. This method utilizes encapsulation techniques and multivariate optimization for enhanced taste profiles.
Overview
This innovative research focuses on improving the flavor profile of cacao derivatives by using β-cyclodextrin (BCD) and other starch derivatives. The goal is to reduce unwanted bitterness and off flavors while maintaining the delightful cacao taste and beneficial antioxidant properties. By forming inclusion complexes, BCD selectively encapsulates non-polar compounds responsible for undesirable tastes, offering a promising solution for the chocolate industry.
Technical specifications
Key features:
- Utilizes β-cyclodextrin, a GRAS oligosaccharide, for encapsulating non-polar bitter compounds in cacao derivatives.
- Employs advanced techniques such as RMN, UV-Visible and FTIR spectroscopies, SEM, and thermal analysis to verify encapsulation.
- Optimization involves multivariate statistical methods to fine-tune conditions like pH, temperature, and time for complex formation.
- Future plans include testing starch nanoparticles and nanocrystals for further enhancement.
Technology readiness level
The technology is currently at TRL 3, indicating it is at an experimental proof of concept stage. Future validation will focus on optimizing process conditions to enhance taste without compromising the beneficial properties of cacao derivatives.
About Universidad de Buenos Aires
Universidad de Buenos Aires (UBA) is a comprehensive public research university and one of Latin America’s largest, with a broad academic footprint and high research intensity. Industry partners engage through campus-embedded laboratories, testing and analysis services, and a dedicated technology transfer entity that brokers contracts, IP licensing, and spinouts. Clinical integration with UBA‑affiliated hospitals and clinics enables access to diverse patient populations and pathways for translational studies, while its citywide footprint places teams near major corporate operations. Research is supported by competitive funding from national science and innovation agencies and international programs. A central corporate engagement function streamlines NDAs, MTAs, and sponsored research agreements to shorten time‑to‑collaboration.
Inquire about this partnering listing
Industry applications
delivered to your inbox.